AYSE MINDIKOGLU to Humans
This is a "connection" page, showing publications AYSE MINDIKOGLU has written about Humans.
Connection Strength
0.430
-
Intermittent fasting from dawn to sunset for four consecutive weeks induces anticancer serum proteome response and improves metabolic syndrome. Sci Rep. 2020 10 27; 10(1):18341.
Score: 0.020
-
Intermittent fasting from dawn to sunset for 30 consecutive days is associated with anticancer proteomic signature and upregulates key regulatory proteins of glucose and lipid metabolism, circadian clock, DNA repair, cytoskeleton remodeling, immune system and cognitive function in healthy subjects. J Proteomics. 2020 04 15; 217:103645.
Score: 0.018
-
Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. Clin Gastroenterol Hepatol. 2020 07; 18(8):1858-1866.e6.
Score: 0.018
-
Predictors of Response to Terlipressin in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 07; 16(7):1174.
Score: 0.016
-
Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675.
Score: 0.016
-
Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018 05; 195:25-47.
Score: 0.016
-
New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 02; 16(2):162-177.e1.
Score: 0.015
-
Prevalence, Severity, and Impact of Renal Dysfunction in Acute Liver Failure on the US Liver Transplant Waiting List. Dig Dis Sci. 2016 Jan; 61(1):309-16.
Score: 0.014
-
Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Dig Dis Sci. 2015 Nov; 60(11):3491-4.
Score: 0.014
-
Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and?Dimethylarginines. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):624-632.e2.
Score: 0.014
-
A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014; 39(6):543-52.
Score: 0.013
-
Outcomes of living versus deceased donor liver transplantation for acute liver failure in the United States. Transplant Proc. 2014 Jan-Feb; 46(1):219-24.
Score: 0.012
-
Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013; 38(4):345-54.
Score: 0.012
-
Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014 Apr; 59(4):1532-42.
Score: 0.012
-
Impact of estimated liver volume and liver weight on gender disparity in liver transplantation. Liver Transpl. 2013 Jan; 19(1):89-95.
Score: 0.011
-
Comparison of seven liver allocation models with respect to lives saved among patients on the liver transplant waiting list. Transpl Int. 2012 Apr; 25(4):409-15.
Score: 0.011
-
Simultaneous liver-kidney versus liver transplantation alone in patients with end-stage liver disease and kidney dysfunction not on dialysis. Transplant Proc. 2011 Sep; 43(7):2669-77.
Score: 0.010
-
Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States. J Pediatr. 2011 May; 158(5):802-7.
Score: 0.010
-
Gender disparity in liver transplant waiting-list mortality: the importance of kidney function. Liver Transpl. 2010 Oct; 16(10):1147-57.
Score: 0.010
-
Radiofrequency ablation in patients with hepatocellular carcinoma. Hepatology. 2009 Dec; 50(6):2053; author reply 2053-4.
Score: 0.009
-
Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl. 2009 Jul; 15(7):719-29.
Score: 0.009
-
Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):128-34; quiz 124.
Score: 0.009
-
Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation. 2008 Feb 15; 85(3):359-68.
Score: 0.008
-
Imatinib mesylate (gleevec) hepatotoxicity. Dig Dis Sci. 2007 Feb; 52(2):598-601.
Score: 0.008
-
Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006 Sep; 4(9):1076-81.
Score: 0.007
-
HELLP syndrome complicated bile duct injury and subsequent left hepatic lobe atrophy. Dig Dis Sci. 2006 Jul; 51(7):1206-12.
Score: 0.007
-
The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. Transplant Proc. 2006 Jun; 38(5):1440-4.
Score: 0.007
-
Multiple normal deliveries in a woman with severe portal hypertension due to congenital hepatic fibrosis: the importance of preserved hepatocellular function. Am J Gastroenterol. 2005 Oct; 100(10):2359-61.
Score: 0.007
-
Focal nodular hyperplasia in identical twins. Am J Gastroenterol. 2005 Jul; 100(7):1616-9.
Score: 0.007
-
Epithelioid hemangioendothelioma of the liver. Clin Gastroenterol Hepatol. 2005 Jul; 3(7):xxxii.
Score: 0.007
-
Post-transplant IVC occlusion and thrombosis treated with tPA, heparin, and sharp recanalization. J Gastroenterol. 2005 Mar; 40(3):302-5.
Score: 0.007
-
Evaluation of novel candidate filtration markers from a global metabolomic discovery for glomerular filtration rate estimation. Kidney Int. 2024 Mar; 105(3):582-592.
Score: 0.006
-
Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. Hepatogastroenterology. 2003 Sep-Oct; 50(53):1338-40.
Score: 0.006
-
Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa. Hepatogastroenterology. 2003 Sep-Oct; 50(53):1697-9.
Score: 0.006
-
Acute intracranial hemorrhage in a cirrhotic controlled with recombinant factor VIIa. Dig Dis Sci. 2003 Jun; 48(6):1130-5.
Score: 0.006
-
Pericardiocentesis and pancreatic aspiration needle biopsy in coagulopathic and thrombocytopenic cirrhotic patient. Chest. 2003 Mar; 123(3):956-8.
Score: 0.006
-
Response to "Reply to: 'The decreasing predictive power of MELD in an era of changing etiology of liver disease'". Am J Transplant. 2020 03; 20(3):903-904.
Score: 0.005
-
The decreasing predictive power of MELD in an era of changing etiology of liver disease. Am J Transplant. 2019 12; 19(12):3299-3307.
Score: 0.005
-
No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg. 2019 01; 269(1):20-27.
Score: 0.004
-
Predicting Liver Allograft Discard: The Discard Risk Index. Transplantation. 2018 09; 102(9):1520-1529.
Score: 0.004
-
Liver transplant length of stay (LOS) index: A novel predictive score for hospital length of stay following liver transplantation. Clin Transplant. 2017 Dec; 31(12).
Score: 0.004
-
A Surge in cadaveric liver donors and a national narcotic epidemic: Is there an association? Liver Transpl. 2017 05; 23(5):698-700.
Score: 0.004
-
Renal dysfunction in cirrhosis. Curr Opin Gastroenterol. 2015 May; 31(3):215-23.
Score: 0.003
-
Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol. 2014 Jun; 31(6):971.
Score: 0.003
-
End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection. J Viral Hepat. 2012 May; 19(5):371-6.
Score: 0.003
-
Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl. 2009 Dec; 15(12):1814-20.
Score: 0.002
-
Postoperative infections in cirrhotic patients. Hepatogastroenterology. 2005 Jul-Aug; 52(64):1240-3.
Score: 0.002
-
Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis. J Gastroenterol Hepatol. 2005 Jun; 20(6):882-9.
Score: 0.002
-
Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study. Cytokine. 2004 Sep 21; 27(6):159-65.
Score: 0.002
-
Cardiovascular problems in cirrhotic patients. Turk J Gastroenterol. 2004 Sep; 15(3):126-32.
Score: 0.002
-
Coagulation and fibrinolysis in individuals with advanced liver disease. Turk J Gastroenterol. 2004 Jun; 15(2):67-72.
Score: 0.002
-
Modulation of endothelial cell inflammatory integrins and stress markers with rh-factor VIIa in patients with advanced chronic hepatitis C. J Viral Hepat. 2003 Jul; 10(4):310-7.
Score: 0.001
-
Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci. 2003 Jul; 48(7):1414-24.
Score: 0.001